XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 25.71

0.0%

Jan 27 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Chris Boylan who wrote (9031)	3/9/1999 6:03:00 PM
From: Cacaito	Read Replies (3) of 17367

"Because of the nature of the illness and the lack of an effective treatment the FDA agreed to let XOMA shoot for an easier target than usual." The only thing FDA granted was to accept the PI as a PII. What we call a PII (the lancet article) was originally a PI. Due to the good results, the lack of treatment and the good number of subjects (total 26, 25 survivors) the FDA allow Xoma to go to PIII. But not a weaker version of a PIII.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next